Phio Pharmaceuticals Corp. PHIO

PHIO Company Overview

Phio Pharmaceuticals Corp. is a clinical-stage biotechnology company focused on developing immuno-oncology therapeutics based on proprietary self-delivering RNA interference (RNAi) technology. The company operates within the biotechnology and pharmaceutical industries, with a primary emphasis on enhancing immune cell activity against cancer. Phio’s core platform, known as INTASYL, is designed to silence specific genes involved in immune suppression without requiring specialized delivery vehicles. The company’s principal revenue activity historically has been derived from financing activities and collaboration-related arrangements rather than commercial product sales, as it does not currently market approved therapies.

The company traces its origins to RXi Pharmaceuticals Corporation, which was founded in 2011 following the merger of Galena Biopharma’s RNAi assets with RXi Pharmaceuticals. The business later rebranded as Phio Pharmaceuticals Corp. to reflect its immuno-oncology focus. Phio has positioned itself around the potential advantages of self-delivering RNAi compounds, including localized administration, reduced delivery complexity, and the ability to enhance adoptive cell therapies such as tumor-infiltrating lymphocytes (TILs) and CAR-T therapies. Public disclosures in SEC filings and corporate presentations indicate that the company primarily targets oncology researchers, clinical collaborators, and biotechnology partners developing cell-based cancer therapies.